- Regulatory Status
- RUO
- Other Names
- B cell maturation antigen (BCMA), tumor necrosis factor receptor superfamily member 17, CD269.
-
Human TNFRSF17 inhibits the B cell proliferation induced by mouse TNFSF13 (APRIL). -
Stability testing for human TNFRSF17. Human TNFRSF17 was aliquoted in PBS, pH7 at 0.2 mg/ml and one aliquot was kept at 4°C (control), and another was freeze/thawed four times (4x freeze/thaws). After this procedure, the samples were tested for their ability to inhibit the proliferation of human B cells induced by TNFSF13 (APRIL).
| Cat # | Size | Price | Quantity Check Availability | ||
|---|---|---|---|---|---|
| 769602 | 10 µg | $94.00 | |||
| 769604 | 25 µg | $194.00 | |||
| 769606 | 100 µg | $698.00 | |||
| 769608 | 500 µg | $1846.00 | |||
Select size of product is eligible for a 40% discount! Promotion valid until December 31, 2024. Exclusions apply. To view full promotion terms and conditions or to contact your local BioLegend representative to receive a quote, visit our webpage.
Human TNFRSF17 is a type I attached membrane protein of 184 amino acids, possesses a conserved motif of six cysteines in the N-terminal, consistent with the formation of a cysteine repeat motif found in the extracellular domain of TNFRs. Overexpression of TNFRSF17 in 293 cells activates NF-kappa B, Elk-1, the c-Jun N-terminal kinase, and the p38 mitogen-activated protein kinase, after its association with TNF Receptor-Associated Factor (TRAF) 1, TRAF2, and TRAF3. Soluble forms of TACI (TNFRSF13B) and TNFRSF17 bind to BAFF (TNFSFL13B) and APRIL (TNFSFL13A); the interaction of TNFRSF17 to APRIL has higher affinity than the TNFRSF17-BAFF interaction. Analysis of BCMA knockout mice (BCMA−/−) showed no differences in the steady-state frequencies or composition of peripheral B cell subsets (immature, marginal zone, follicular, B1). TNFRSF17 expression is upregulated on PBMCs from mice that develop a Sjogren’s-like syndrome, patients with Sjogren’s syndrome, with rheumatoid arthritis, and on B cells from SLE patients. Patients with multiple myeloma show elevated serum BCMA levels and it correlated with the proportion of plasma cells in bone marrow biopsies and clinical status. Serum BCMA levels in considered a novel biomarker to predict outcomes for multiple myeloma patients.
Product Details
- Source
- Human TNFRSF17, amino acids (Met1 – Ala54) (Accession # NP_001183) was expressed in 293E cells. Human IgG-Fc is in the carboxyl-terminus.
- Molecular Mass
- The 293 amino acid recombinant protein has a predicted molecular mass of approximately 32.7 kD. The DTT-reduced and non-reduced protein migrate at approximately 40-45 kD and 80-85 kD respectively by SDS-PAGE. The predicted N-terminal amino acid is Met.
- Purity
- > 95% by SDS-PAGE gel as determined by Coomassie stained SDS-PAGE.
- Formulation
- 0.22 µm filtered protein solution is in PBS pH 7.2.
- Endotoxin Level
- Less than 0.10 EU per µg of protein as determined by the LAL method.
- Concentration
- 10 and 25 µg sizes are bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
- Storage & Handling
- Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
- Activity
- Human TNFRSF17 inhibits the B cell proliferation (measured with Deep Blue Cell Viability™ Kit, Cat. No. 424701) induced by mouse TNF SF13 (APRIL) in a dose dependent manner. The ED50= 8 - 40 ng/ml.
- Application
-
Bioassay
- Application Notes
-
BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are verified in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at tech@biolegend.com.
Antigen Details
- Structure
- Homodimer
- Distribution
-
Resting and activated B cells, malignant B lymphocytes, plasma cells.
- Function
- Maintains the peripheral B cell population and survival of long-lived bone marrow plasma cells. Soluble BCMA acts as a decoy receptor for APRIL. TNFRSF17 mRNA is stimulated by IL-4 and IL-6 in murine B cells.
- Interaction
- Monocytes, macrophages, T cells, and dendritic cells.
- Ligand/Receptor
- TNFSF13 (APRIL), TNFSF (BAFF)
- Bioactivity
- Inhibits the B cell proliferation induced by mouse TNFSF13 (APRIL) .
- Biology Area
- Immunology
- Molecular Family
- Soluble Receptors
- Antigen References
-
- Madry C, et al. 1998. Int Immunol. 10:1693.
- Hatzoglou A, et al. 2000. J Immunol. 165:1322.
- Rennert P, et al. 2000. J Exp Med. 192:1677.
- Wallweber HJ, et al. 2004. J Mol Biol. 2004 343:283.
- O'Connor BP, et al. 2004. J Exp Med. 199:91.
- Kim J, et al. 2011. Autoimmunity. 44:69.
- Coqueri CM, and Erickson LD. 2012. Crit Rev Immunol. 32:287.
- Laurent SA, et al. 2015. Nature Commun. 6:7333.
- Ghermezi M, et al. 2017. Hematologica. 102:785.
- Gene ID
- 608 View all products for this Gene ID
- UniProt
- View information about TNFRSF17 on UniProt.org